文献速递毛发、甲与色素性疾病

白癜风患者对现有治疗的看法及对新疗法的需求

Patients' perspective on current treatments and demand for novel treatments in vitiligo.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-10-07

该前瞻性问卷研究纳入325例连续就诊的白癜风患者,评估其对现有及新型治疗的看法。94%认为需要新疗法,86%愿意参与临床试验,49%认为现有治疗无效,50%不满意;深肤色患者情感负担显著更高(8 vs 5,P<0.05)。

要点

  • 94%白癜风患者认为需要新疗法,86%愿意参与临床试验。
  • 49%既往治疗者认为现有治疗无效,50%不满意现有治疗。

核心结论

  • 白癜风患者对新疗法需求大,多数不满现有治疗且情感负担重。

研究设计与样本

  • 前瞻性问卷研究,纳入2017年4月至2019年1月在阿姆斯特丹大学医学中心连续就诊的白癜风患者,共325例完成问卷(应答率60%)。

主要发现

  • 94%受访者认为需要新和改进疗法,86%愿意参与新疗法临床试验。
  • 49%既往治疗者报告现有治疗无效,50%不满意现有治疗。
  • 深肤色患者情感负担评分显著高于浅肤色患者(8 vs 5,U P < 0.05)。

临床怎么用

  • 临床中应关注白癜风患者对现有治疗的不满及情感负担,尤其是深肤色患者。
  • 可向患者提供临床试验信息,多数患者愿意参与新疗法研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The treatment of non-segmental vitiligo (NSV) remains a challenge. Current treatments often achieve suboptimal clinical results. To improve these treatment results, several new therapies are being developed and investigated. There is, however, little evidence on the actual need for novel therapies. OBJECTIVE: To assess patients' perspective on current and novel therapies for vitiligo. METHODS: A prospective questionnaire study was conducted in a large cohort of vitiligo patients that consecutively visited the outpatient clinic of the Amsterdam University Medical Centre between April 2017 and January 2019. Patients were requested to fill in a digital questionnaire on patient characteristics, disease burden, quality of life, efficacy and satisfaction of current treatments and aspects regarding new treatments. RESULTS: A total of 325 vitiligo patients completed the questionnaire (60% response rate). Of the respondents, 94% believed that new and improved treatments are needed and 86% would be willing to participate in clinical trials investigating a new therapy. Sixty-nine per cent would agree on taking weekly injections if it led to effective treatment results. Of the patients that had received therapy before, 49% reported that the current treatments were not effective and 50% was not satisfied with the current treatments. Sixty-seven per cent of the patients experienced facial lesions as an extreme burden, whereas this was, 25%, 12% and 10% for lesions on the hands, trunk and feet, respectively. The emotional burden score was significantly higher in dark skin types compared with light skin types (respectively, 8 vs 5, U P < 0.05). CONCLUSION: There is a substantial need for new vitiligo therapies. A considerable number of patients in our study are dissatisfied with current treatments and are emotionally burdened by the disease. Moreover, the vast majority demands novel treatments and is willing to participate in clinical trials.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Narayan VS, Uitentuis SE, Luiten RM, et al. Patients' perspective on current treatments and demand for novel treatments in vitiligo. J Eur Acad Dermatol Venereol. 2020. PMID: 32893377. doi:10.1111/jdv.16927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。